Drug Trial Radar · NCT05676034
AMX0035 in Adult Patients With Wolfram Syndrome
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Actual
Start
Mar 3, 2023
Primary completion
Jul 23, 2024
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open label Phase II study to evaluate the safety and efficacy of AMX0035 in adults with Wolfram syndrome.
Conditions
- Wolfram Syndrome
Interventions
AMX0035Drug
AMX0035
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of AMX0035 on residual beta-cell function by monitoring C-peptide levels during a 0-240 minutes mixed-meal tolerance test (MMTT)Time frame: 24 weeks
- To assess the safety and tolerability of AMX0035 administered orally for up to 208 weeks in adult participants with Wolfram syndromeTime frame: 208 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.